Stressed Liver and Muscle Call on Adipocytes with FGF21

Fibroblast growth factor 21 (FGF21) is an emerging regulator of local and systemic metabolic homeostasis. Treatment with pharmacological levels of FGF21 alleviates obesity and associated metabolic diseases including diabetes. However, beyond anti-obesogenic effects, the normal roles and underlying m...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 4; p. 194
Main Authors Luo, Yongde, McKeehan, Wallace L
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 18.12.2013
Subjects
Adipose Tissue
diabetes
Endocrinology
Liver
Metabolism
Muscle
Obesity
adipose FGFR1
stress response
diabetes
obesity
FGF21
Online AccessGet full text

Cover

More Information
Summary:Fibroblast growth factor 21 (FGF21) is an emerging regulator of local and systemic metabolic homeostasis. Treatment with pharmacological levels of FGF21 alleviates obesity and associated metabolic diseases including diabetes. However, beyond anti-obesogenic effects, the normal roles and underlying mechanisms of FGF21 as an endocrine hormone remain unclear. A recent wave of studies has revealed that FGF21 is a stress-induced endocrine factor in liver, muscle, and other tissues that targets adipose tissue and adipocytes through the FGFR1-betaKlotho complex. Adipose tissues and adipocytes within diverse tissues respond with metabolites and adipokine signals that affect functions of body tissues systemically and cells within the local microenvironment adjacent to adipocytes. Normally this is to prevent impaired tissue-specific function and damage to diverse tissues secreting FGF21 in response to chronic stress. Therefore, diverse stressed tissues and the adipose tissue and adipocytes constitute a beneficial endocrine and paracrine communication network through FGF21. Here we attempt to unify these developments with beneficial pharmacological effects of FGF21 on obesity in respect to inter-organ stress communication and mechanisms.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Gary Sweeney, Institut Pasteur, South Korea, York University, Canada
This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology.
Reviewed by: Minho Shong, Research Center for Endocrine and Metabolic Diseases, South Korea; Stephan Wueest, University Children’s Hospital Zurich, Switzerland
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2013.00194